Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study

Next Previous
Trial Profile

The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Becotatug vedotin (Primary) ; Pucotenlimab (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Carcinoma; Salivary gland cancer
  • Focus Therapeutic Use
  • Acronyms TSEMPRMSGC

Most Recent Events

  • 01 Apr 2026 Number of treatment arms are increased from 2 to 4 by the addition of 2 more experimental arms namely- "Experimental: MRG003 Monotherapy in Non-ACC SGC" and "Experimental: MRG003 combined with Pucontenlimab in Non-ACC SGC".
  • 01 Apr 2026 Planned number of patients changed from 68 to 90.
  • 01 Apr 2026 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top